Skip to main content
Top
Published in: Cancer Causes & Control 4/2017

01-04-2017 | Original paper

Functional germline variants in driver genes of breast cancer

Authors: Stella Göhler, Miguel Inacio Da Silva Filho, Robert Johansson, Kerstin Enquist-Olsson, Roger Henriksson, Kari Hemminki, Per Lenner, Asta Försti

Published in: Cancer Causes & Control | Issue 4/2017

Login to get access

Abstract

Purpose

Germline mutations in tumour suppressor genes cause various cancers. These genes are also somatically mutated in sporadic tumours. We hypothesized that there may also be cancer-related germline variants in the genes commonly mutated in sporadic breast tumours.

Methods

After excluding the well-characterized breast cancer (BC) genes, we screened 15 novel genes consistently classified as BC driver genes in next-generation sequencing approaches for single nucleotide polymorphisms (SNPs). Altogether 40 SNPs located in the core promoter, 5′- and 3′-UTR or which were nonsynonymous SNPs were genotyped in 782 Swedish incident BC cases and 1,559 matched controls. After statistical analyses, further evaluations related to functional prediction and signatures of selection were performed.

Results

TBX3 was associated with BC risk (rs2242442: OR = 0.76, 95% CI 0.64–0.92, dominant model) and with less aggressive tumour characteristics. An association with BC survival and aggressive tumour characteristics was detected for the genes ATR (rs2227928: HR = 1.63; 95% CI 1.00–2.64, dominant model), RUNX1 (rs17227210: HR = 3.50, 95% CI 1.42–8.61, recessive model) and TTN (rs2303838: HR = 2.36; 95% CI 1.04–5.39; rs2042996: HR = 2.28; 95% CI 1.19–4.37, recessive model). According to the experimental ENCODE data all these SNPs themselves or SNPs in high linkage disequilibrium with them (r 2 ≥ 0.80) were located in regulatory regions. RUNX1 and TTN showed also several signatures of positive selection.

Conclusion

The study gave evidence that germline variants in BC driver genes may have impact on BC risk and/or survival. Future studies could discover further germline variants in known or so far unknown driver genes which contribute to cancer development.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ren JS, Masuyer E et al (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 1325:1133–1145CrossRef Bray F, Ren JS, Masuyer E et al (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 1325:1133–1145CrossRef
2.
go back to reference Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Internet; Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 05 Feb 2014 Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Internet; Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed 05 Feb 2014
3.
go back to reference Frank C, Fallah M, Ji J et al (2014) The population impact of familial cancer, a major cause of cancer. Int J Cancer 1348:1899–1906CrossRef Frank C, Fallah M, Ji J et al (2014) The population impact of familial cancer, a major cause of cancer. Int J Cancer 1348:1899–1906CrossRef
4.
go back to reference Olivier M, Hollstein MHainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 21:a001008 Olivier M, Hollstein MHainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 21:a001008
5.
go back to reference Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 3145797:268–274CrossRef Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 3145797:268–274CrossRef
6.
go back to reference Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 3185853:1108–1113CrossRef Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 3185853:1108–1113CrossRef
7.
go back to reference Teschendorff A, ECaldas C (2009) The breast cancer somatic ‘muta-ome’: tackling the complexity. Breast Cancer Res 112:301CrossRef Teschendorff A, ECaldas C (2009) The breast cancer somatic ‘muta-ome’: tackling the complexity. Breast Cancer Res 112:301CrossRef
8.
go back to reference Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 4587239:719–724CrossRef Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 4587239:719–724CrossRef
9.
go back to reference Tomasetti C, Marchionni L, Nowak MA et al (2015) Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci USA 1121:118–123CrossRef Tomasetti C, Marchionni L, Nowak MA et al (2015) Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci USA 1121:118–123CrossRef
10.
go back to reference Banerji S, Cibulskis K, Rangel-Escareno C et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 4867403:405–409CrossRef Banerji S, Cibulskis K, Rangel-Escareno C et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 4867403:405–409CrossRef
11.
go back to reference Ellis MJ, Ding L, Shen D et al (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 4867403:353–360 Ellis MJ, Ding L, Shen D et al (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 4867403:353–360
12.
go back to reference Shah SP, Roth A, Goya R et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 4867403:395–399 Shah SP, Roth A, Goya R et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 4867403:395–399
13.
go back to reference Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 4867403:400–404 Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 4867403:400–404
14.
go back to reference Kaaks R, Lundin E, Rinaldi S et al (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 134:307–316CrossRef Kaaks R, Lundin E, Rinaldi S et al (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 134:307–316CrossRef
15.
go back to reference Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 813:559–575CrossRef Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 813:559–575CrossRef
16.
go back to reference McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 9716:1180–1184CrossRef McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 9716:1180–1184CrossRef
17.
go back to reference Voight BF, Kudaravalli S, Wen X et al (2006) A map of recent positive selection in the human genome. PLoS Biol 43:e72CrossRef Voight BF, Kudaravalli S, Wen X et al (2006) A map of recent positive selection in the human genome. PLoS Biol 43:e72CrossRef
18.
go back to reference Oleksyk TK, Smith M WO’Brien SJ (2010) Genome-wide scans for footprints of natural selection. Philos Trans R Soc Lond B Biol Sci 3651537:185–205CrossRef Oleksyk TK, Smith M WO’Brien SJ (2010) Genome-wide scans for footprints of natural selection. Philos Trans R Soc Lond B Biol Sci 3651537:185–205CrossRef
19.
go back to reference Dai YGrant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 162:376–383 Dai YGrant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 162:376–383
20.
go back to reference Peasland A, Wang LZ, Rowling E et al (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 1053:372–381CrossRef Peasland A, Wang LZ, Rowling E et al (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 1053:372–381CrossRef
21.
go back to reference Heikkinen K, Mansikka V, Karppinen SM et al (2005) Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res 74:R495–R501CrossRef Heikkinen K, Mansikka V, Karppinen SM et al (2005) Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res 74:R495–R501CrossRef
22.
go back to reference Durocher F, Labrie Y, Soucy P et al (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6:230CrossRefPubMedPubMedCentral Durocher F, Labrie Y, Soucy P et al (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6:230CrossRefPubMedPubMedCentral
23.
go back to reference Grimm-Gunter E M, Revenu C, Ramos S, et al., (2009) Plastin 1 binds to keratin and is required for terminal web assembly in the intestinal epithelium. Mol Biol Cell. 2010:2549–2562CrossRef Grimm-Gunter E M, Revenu C, Ramos S, et al., (2009) Plastin 1 binds to keratin and is required for terminal web assembly in the intestinal epithelium. Mol Biol Cell. 2010:2549–2562CrossRef
24.
go back to reference Wang L, Brugge J SJanes KA (2011) Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 10840:E803–E812CrossRef Wang L, Brugge J SJanes KA (2011) Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 10840:E803–E812CrossRef
25.
go back to reference Ramaswamy S, Ross KN, Lander ES et al (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 331:49–54 Ramaswamy S, Ross KN, Lander ES et al (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 331:49–54
26.
go back to reference Chimge N, OFrenkel B (2013) The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 3217:2121–2130CrossRef Chimge N, OFrenkel B (2013) The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 3217:2121–2130CrossRef
27.
go back to reference Shield PW, Papadimos D JWalsh MD, (2014) GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer Cytopathol Shield PW, Papadimos D JWalsh MD, (2014) GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer Cytopathol
28.
go back to reference Tamborero D, Gonzalez-Perez A, Perez-Llamas C et al (2013) Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 3:2650PubMedPubMedCentral Tamborero D, Gonzalez-Perez A, Perez-Llamas C et al (2013) Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 3:2650PubMedPubMedCentral
29.
go back to reference Douglas N, CPapaioannou VE (2013) The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 182:143–147CrossRef Douglas N, CPapaioannou VE (2013) The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 182:143–147CrossRef
30.
go back to reference Washkowitz AJ, Gavrilov S, Begum S et al (2012) Diverse functional networks of Tbx3 in development and disease. Wiley Interdiscip Rev Syst Biol Med 43:273–283CrossRef Washkowitz AJ, Gavrilov S, Begum S et al (2012) Diverse functional networks of Tbx3 in development and disease. Wiley Interdiscip Rev Syst Biol Med 43:273–283CrossRef
31.
go back to reference Kandoth C, McLellan MD, Vandin F et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 5027471:333–339CrossRef Kandoth C, McLellan MD, Vandin F et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 5027471:333–339CrossRef
32.
go back to reference Lawrence MS, Stojanov P, Mermel CH et al (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 5057484:495–501CrossRef Lawrence MS, Stojanov P, Mermel CH et al (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 5057484:495–501CrossRef
33.
go back to reference Hosford S RMiller T W, (2014) Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 7:203–215PubMedPubMedCentral Hosford S RMiller T W, (2014) Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 7:203–215PubMedPubMedCentral
34.
go back to reference Endo Y, Toyama T, Takahashi S et al (2013) miR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer. Endocr Relat Cancer 201:91–102CrossRef Endo Y, Toyama T, Takahashi S et al (2013) miR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer. Endocr Relat Cancer 201:91–102CrossRef
35.
go back to reference Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 4467132:153–158CrossRef Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 4467132:153–158CrossRef
36.
go back to reference Dowling JJ (2013) Titin and centronuclear myopathy: the tip of the iceberg for TTN-ic mutations? Neurology 8114:1189–1190CrossRef Dowling JJ (2013) Titin and centronuclear myopathy: the tip of the iceberg for TTN-ic mutations? Neurology 8114:1189–1190CrossRef
37.
go back to reference Mayans O, van der Ven PF, Wilm M et al (1998) Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature 3956705:863–869 Mayans O, van der Ven PF, Wilm M et al (1998) Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature 3956705:863–869
38.
go back to reference Machado C, Andrew DJ (2000) Titin as a chromosomal protein. Adv Exp Med Biol 481:221–232 (discussion 232–236) CrossRefPubMed Machado C, Andrew DJ (2000) Titin as a chromosomal protein. Adv Exp Med Biol 481:221–232 (discussion 232–236) CrossRefPubMed
40.
go back to reference Lawrence MS, Stojanov P, Polak P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 4997457:214–218CrossRef Lawrence MS, Stojanov P, Polak P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 4997457:214–218CrossRef
Metadata
Title
Functional germline variants in driver genes of breast cancer
Authors
Stella Göhler
Miguel Inacio Da Silva Filho
Robert Johansson
Kerstin Enquist-Olsson
Roger Henriksson
Kari Hemminki
Per Lenner
Asta Försti
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 4/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0849-3

Other articles of this Issue 4/2017

Cancer Causes & Control 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine